SEC Comment Letter 0000000000-24-014294 to INNOVATIVE MEDTECH, INC. (IMTH) (CIK 0001331612)
INNOVATIVE MEDTECH, INC. (IMTH) (CIK 0001331612)
Date: Dec. 27, 2024 · CIK: 0001331612 · Accession: 0000000000-24-014294
AI Filing Summary & Sentiment
File numbers found in text: 024-12549
Letter
December 27, 2024 Michael Friedman Chief Executive Officer Innovative MedTech, Inc. 2310 York St. Suite 200 Blue Island, IL 60406 Re:Innovative MedTech, Inc. Offering Statement on Form 1-A Filed December 20, 2024 File No. 024-12549 Dear Michael Friedman: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Nicholas O'Leary at 202-551-4451 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Lance Brunson, Esq.
Show Raw Text
December 27, 2024
Michael Friedman
Chief Executive Officer
Innovative MedTech, Inc.
2310 York St. Suite 200
Blue Island, IL 60406
Re:Innovative MedTech, Inc.
Offering Statement on Form 1-A
Filed December 20, 2024
File No. 024-12549
Dear Michael Friedman:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff. We also remind you that, following qualification of your Form 1-A,
Rule 257 of Regulation A requires you to file periodic and current reports, including a Form
1-K which will be due within 120 calendar days after the end of the fiscal year covered by the
report.
Please contact Nicholas O'Leary at 202-551-4451 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Lance Brunson, Esq.